Evidence map›Paper›PMID 36897529›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023

Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.

M K Lee, E Basch, S A Mitchell, L M Minasian, B T Langlais, G Thanarajasingam, B F Ginos, L J Rogak, T R Mendoza, A V Bennett and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Introduction and validation of the open symptom framework: a public domain modular framework for patient-reported measurement of symptoms related to cancer and its treatment.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

M K LeeDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. lee.minji@mayo.edu.ORCID http://orcid.org/0000-0002-1301-4319
E BaschUNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
S A MitchellNational Cancer Institute, Rockville, MD, USA.
L M MinasianNational Cancer Institute, Rockville, MD, USA.
B T LanglaisDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
G ThanarajasingamDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
B F GinosDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
L J RogakMemorial Sloan Kettering Cancer Center, New York, NY, USA.
T R MendozaMD Anderson Cancer Center, Houston, TX, USA.
A V BennettUNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
D SchragMemorial Sloan Kettering Cancer Center, New York, NY, USA.
G L MazzaDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
A C DueckDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Mayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · USUNC Lineberger Comprehensive Cancer CenterThe University of Texas MD Anderson Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug TolerabilityU01CA233046 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BASCH, ETHAN M., DUECK, AMYLOU CONSTANCE · 2018 to 2023
$3.0M
NCI NIH HHS HHSN261200800043CNCI NIH HHS P30 CA008748NCI NIH HHS U01 CA233046
6 · The paper itself

Abstract

purposeThe standard recall period for the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) is the past 7 days, but there are contexts where a 24-hour recall may be desirable. The purpose of this analysis was to investigate the reliability and validity of a subset of PRO-CTCAE items captured using a 24-hour recall.

methods27 PRO-CTCAE items representing 14 symptomatic adverse events (AEs) were collected using both a 24-hour recall (24 h) and the standard 7 day recall (7d) in a sample of patients receiving active cancer treatment (n = 113). Using data captured with a PRO-CTCAE-24h on days 6 and 7, and 20 and 21, we computed intra-class correlation coefficients (ICC); an ICC ≥ 0.70 was interpreted as demonstrating high test-retest reliability. Correlations between PRO-CTCAE-24h items on day 7 and conceptually relevant EORTC QLQ-C30 domains were examined. In responsiveness analysis, patients were deemed changed if they had a one-point or greater change in the corresponding PRO-CTCAE-7d item (from week 0 to week 1).

resultsPRO-CTCAE-24h captured on two consecutive days demonstrated that 21 of 27 items (78%) had ICCs ≥ 0.70 (day 6/7 median ICC 0.76), (day 20/21 median ICC 0.84). Median correlation between attributes within a common AE was 0.75, and the median correlation between conceptually relevant EORTC QLQ-C30 domains and PRO-CTCAE-24 h items captured on day 7 was 0.44. In the analysis of responsiveness to change, the median standardized response mean (SRM) for patients with improvement was - 0.52 and that for patients with worsening was 0.71.

conclusionA 24-hour recall period for PRO-CTCAE items has acceptable measurement properties and can inform day-to-day variations in symptomatic AEs when daily PRO-CTCAE administration is implemented in a clinical trial.

Indexed as

Antineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsNeoplasmsAdverse Drug Reaction Reporting SystemsHumansPatient Reported Outcome MeasuresQuality of LifeReproducibility of ResultsSurveys and QuestionnairesAntineoplastic Agents24-hour recallDaily diaryPRO-CTCAEReliabilityValidity

Identifiers

PMID36897529
PMCPMC10241696
OpenAlexW4323812246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.